AstraZeneca to acquire 55% stake in Acerta Pharma
Following the news earlier this week that AstraZeneca had been in acquisition talks with Acerta Pharma, AstraZeneca today announced that it is to invest in a majority equity stake in the company.
List view / Grid view
News
Big data reconfirms accuracy of Oncotype DX breast cancer test
17 December 2015 | By Victoria White
Genomic Health has announced results from multiple Oncotype DX breast cancer test studies that reconfirm the Oncotype DX test accurately predicts clinical outcomes in patients with early-stage invasive breast cancer...
AstraZeneca to acquire Takeda’s respiratory business
17 December 2015 | By Victoria White
AstraZeneca is to acquire the core respiratory business of Takeda for $575 million, adding Daxas to its portfolio...
High throughput single cell applications set to benefit from Dolomite’s novel µEncapsulator 1 System
16 December 2015 | By Dolomite
Dolomite, a world leader in microfluidics innovation, has launched the groundbreaking µEncapsulator 1 System, the only microfluidic product specifically designed to meet the needs of research biologists...
Quotient Clinical expands its formulation development services with the acquisition of Co-Formulate
16 December 2015 | By Quotient Clinical
Quotient Clinical, the Translational Pharmaceutics® company, has announced that it has acquired formulation development specialist Co-Formulate Limited...
NICE says ‘yes’ to Santen’s dry eye disease treatment, ciclosporin
16 December 2015 | By Victoria White
Ciclosporin (Ikervis) is a sterile, positively charged, oil-in water, unpreserved ophthalmic emulsion that contains ciclosporin (CsA)...
Versatile Syrris flow reactors feature in a plethora of publications
15 December 2015 | By Versatile Syrris
Today, scientists have access to hundreds of flow chemistry papers citing groundbreaking applications established on modular reactors from Syrris, including the Ley group’s Accelerating Spirocyclic Polyketide Synthesis using Flow Chemistry...
Comic Relief and GSK team up to help fight malaria
15 December 2015 | By Victoria White
A new fund – created through a £17m donation from GSK and £5m from Comic Relief – will provide targeted grants over the next five years to organisations on the malaria frontline...
Pharmaceutical deals crucial to offset R&D costs, says GBI Research
15 December 2015 | By Victoria White
GBI Research’s latest report states that pharmaceutical companies are considering various strategies to overcome the challenge of rising R&D costs, with deal-making the foremost method of boosting short-term revenues...
Allergan’s Viberzi (eluxadoline) now available in the US
15 December 2015 | By Victoria White
Viberzi, a twice daily, oral medication, is Allergan’s first-in-class treatment for irritable bowel syndrome with diarrhoea (IBS-D)...
Amgen reacquires product rights to 3 products from GSK
15 December 2015 | By Victoria White
Amgen has entered into a definitive agreement with GSK to reacquire all of its remaining rights to Prolia (denosumab), XGEVA (denosumab) and Vectibix (panitumumab) in 48 countries...
Sanofi and Boehringer Ingelheim announce business swap
15 December 2015 | By Victoria White
The proposed transaction would consist of an exchange of Sanofi animal health business (Merial) and Boehringer Ingelheim consumer healthcare (CHC) business...
Trial of Ofev and pirfenidone in IPF starts
14 December 2015 | By Victoria White
The trial’s primary endpoint is the percentage of patients with on-treatment gastrointestinal adverse events from baseline to week 12...
FDA approves Vistogard to treat 5-FU or capecitabine overdoses
14 December 2015 | By Victoria White
Vistogard is the first and only antidote for 5-FU and capecitabine overdose and for earlyonset, severe, life-threatening toxicities approved by the FDA...
Nurofen Australia made misleading Specific Pain claims
14 December 2015 | By Victoria White
The Australian Federal Court has found that Reckitt Bensicker (Australia) engaged in misleading conduct in contravention of Australia Consumer Law by representing that its Nurofen Specific Pain Products were each formulated to treat a specific type of pain...
